Skip to content

Long Acting Cabotegravir plus Rilpivirine in People Living with HIV-1 (PLHIV) Aged ≥ 60 Years for 96 weeks.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-502882-53-00
Acronym
IMIB-LOVER60-2022-03
Enrollment
120
Registered
2025-01-15
Start date
2025-03-03
Completion date
Unknown
Last updated
2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV-1

Brief summary

Proportion of PLHIV ≥ 60 years on stable ART that switch to CAB LA + RPV LA with plasma HIV-1 RNA ≥50 copies per mL at month 12 in the intention-to-treat exposed (ITT-E) population, per the US Food and Drug Administration’s Snapshot algorithm.

Interventions

Sponsors

Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Proportion of PLHIV ≥ 60 years on stable ART that switch to CAB LA + RPV LA with plasma HIV-1 RNA ≥50 copies per mL at month 12 in the intention-to-treat exposed (ITT-E) population, per the US Food and Drug Administration’s Snapshot algorithm.

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026